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X-linked agammaglobulinemia (XLA) is a primary immune deﬁciency characterized by recurrent bacterial infections and
profoundly depressed serum immunoglobulin levels and circulating mature B cells. We describe a 12-year-old boy with XLA and
enthesitis-related arthritis (ERA). To date, there has been a paucity of reports of noninfectious inﬂammatory arthritis in children
with XLA. This case illustrates that functional B cells and/or immunoglobulinare not required for ERA pathogenesis.In addition,
this case suggests a possible link between immune deﬁciency, immune dysregulation, and rheumatic illness.
1.Introduction
The adaptive immune response consists of humoral immu-
nity mediated by B lymphocytes and cellular immunity
maintained by T lymphocytes. Immunoglobulins, products
of B-cell progeny, plasma cells are the main mediators
of humoral immunity. B-cell deﬁciencies or dysfunction
lead to recurrent bacterial infections with encapsulated
organisms such as S. pneumoniae, M. catarrhalis, and H.
inﬂuenza [1, 2]. Agammaglobulinemia was the ﬁrst pri-
mary immunodeﬁciency to be described. In 1952, Colonel
Ogden Bruton noted the absence of the “gammaglobulin”
fraction on protein electrophoresis in a boy with recurrent
bacterial sinopulmonary infections [3]. Subsequently, the
gene responsible for XLA was identiﬁed and named Bruton’s
tyrosine kinase (BTK) at Xq21.3. This tyrosine kinase is
required for maturation of the B-cell lineage. The prevalence
of XLA has been estimated at 1 case per 250,000 individuals
in the United States.
The recurrent bacterial infections typical of XLA begin
after 6 months of age when the maternally acquiredtranspla-
cental antibody levels decrease and the infant is unable to
synthesize antibodies normally.
ERA is a rare autoimmune disease with an estimated
prevalence of 0.1-0.2% in the general population. ERA
usually presents with oligoarthritis or mild inﬂammatory
back pain. Enthesitis, which refers to inﬂammation of the
areas of attachment of the ligaments, tendons, and fascia to
the bone, is an important feature of the disease.
2.Case Report
A 12-year-old Caucasian boy with XLA and a history of
recurrent knee eﬀusions presented to Rheumatology Service
at nine years of age. He had been diagnosed with XLA at two
years of age when he presented with recurrent methicillin-
resistant Staphylococcal aureus (MRSA)skin abscesses, upper
respiratory infections, and otitis media. He was found to
have neutropenia (absolute neutrophil count 0) and very
low serum immunoglobulin levels: IgG 36mg/dL (normal
600–1200mg/dL),IgA7mg/dL(normal70–300mg/dL),and
IgM 15mg/dL (normal 50mg/dL–300mg/dL). Circulating
CD19+ lymphocytes were undetectable. Genetic testing
demonstrated a previously described mutation in BTK.
Treatment with immunoglobulin replacement therapy
resulted in rapid reversal of circulating neutrophil num-
bers. Maintenance therapy, currently with subcutaneous
immunoglobulin infusions weekly, has prevented recurrence
of severe infections.2 International Journal of Rheumatology
Table 1: Laboratory evaluation of the synovial ﬂuid and blood performed in a 12-year-old boy with X-linked agammaglobulinemia and
recurrent knee eﬀussions over a period of 5 years.
Lab investigations 04/2010 03/2008 08/2007 03/2006 07/2005
Synovial ﬂuid WBC (cells/mm3) 110 30,960 27,000 40,000 220
Synovial ﬂuid culture Neg Neg Neg Neg Neg
Crypto/Cocci Ag/fungal stain and Cx Neg Neg Neg Neg Neg
Atypical mycobacterium/mycoplasmas/ureaplasma Neg Neg Neg Neg Neg
AFB Neg Neg neg neg neg
ESR mm/hr-CRP mg/dL 60/5.1 41/4.1 30/13.5 34/7.5 40/2.3
Blood culture and viral cultures Neg Neg Neg Neg Neg
The patient presented to the Rheumatology Service with
a two-year history of recurrent left knee eﬀusions. His ﬁrst
episode was at seven years of age when he presented with a
one-month history of left knee pain and limp that was not
associated with fever or trauma. He subsequently developed
jointswelling and afteroneweek presented tothe Emergency
Department where synovial ﬂuid from the aﬀected knee was
negative for bacteria, fungus, ureaplasma, and mycoplasma
(see Table 1). The synovial ﬂuid was sent to well-equipped
laboratory, and the ﬂuid was sent by appropriate culture
medium and was incubated for adequate period of time.
Eight months later, the patient’s left knee swelling
recurred two days after he had played on a trampoline.
Synovial ﬂuid cultures were again negative for an infectious
etiology. Magnetic resonance imaging (MRI) was sugges-
tive of a left distal femoral epiphyseal osteomyelitis. He
was treated with clindamycin for six weeks and clinically
improved.
At nine and one-half and at 10 years of age the patient
developed left knee swelling which was not associated
with fever, redness, or limitation of activity. His symptoms
resolved with oral tolmetin in the anti-inﬂammatory dose,
and no further evaluations were performed for infectious
etiologies.
At 12 years of age he presented with pain involving
multiple joints. Four weeks prior, he had sustained trauma
to his right foot which resulted in right big toe pain and
swelling. Two weeks later, he developed pain in left hip and
lower back and a week after, pain in his right shoulder.
Ibuprofen failed to control or improve his symptoms, and
he became unable to move his right shoulder or ambulate.
Diagnostic studies for infections were again unhelpful.
MRI of the right foot was consistent with posttraumatic
joint eﬀusion and marrow contusion, and pelvic MRI was
suggestive of left hip inﬂammatory arthropathy and bilateral
sacroiliitis. The patientimproved onnaproxen aloneand was
discharged home on hospital day three.
He was evaluated at each episode to rule out infection
and trauma. His ophthalmology examination was negative
for ocular inﬂammation in multiple occasions.
OtherthanXLA,thepatienthadnootherknownmedical
conditions and no known bleeding disorders. He was up to
date in immunizations up to 2 yrs of age and had no medi-
cation allergies. Family history was signiﬁcant for colitis and
spinal arthritis in a maternal aunt and psoriasis in a maternal
cousin. The patient’s half-brother also has XLA. There is no
family history of bleeding disorders. Although he continued
to receive immunoglobulin replacement for XLA, this did
not prevent recurrent episodes of synovitis. The patient
responded well to acute anti-inﬂammatory treatment, but
he was nonadherent with maintenance therapy and followup
outpatient visits. Other disease-modifying antirheumatic
drugs (DMARDs) and biologic therapies that are indicated
in the management of childhood ERA were not used because
of his good response to tolmetin and the signiﬁcant potential
for increased risk for infections associated with his primary
immune deﬁciency. The diagnosis of ERA was based on the
patient’s recurrent knee inﬂammation, lack of an infectious
etiology, clinical enthesitis, sacroiliitis, HLA-B27 positivity,
and a family history of psoriasis and colitis.
3.Discussion
ERA encompasses a heterogeneous group of inﬂammatory
diseases characterized by axial and asymmetric peripheral
arthritis, enthesitis, and at times, ocular, gastrointestinal,
or cardiac manifestations. These disorders show a familial
aggregation and are typically associated with HLA genes of
the major histocompatibility complex (MHC), particularly
HLA-B27. MHC class I molecules present antigenic epitopes
to antigen-speciﬁc CD8+ cytotoxic T cells (CTLs) and thus
determine which antigens will elicit a CTL response.
In the absence of a functional Bruton’s tyrosine kinase
gene, mature B cells that express surface Ig and CD19are few
toabsent.TheabsenceofCD19+cellsisreadilydetectedwith
ﬂuorocytometric assays, and this ﬁnding strongly suggests
XLAinanaﬀectedmale.BTK mutationanalysisconﬁrmsthe
diagnosis.
This case illustrates that mature B-cells and immuno-
globulinsare notrequiredforERApathogenesis.Inaddition,
thiscaseprovidesapossiblelinkbetweenimmunedeﬁciency,
immune dysregulation, and rheumatic illnesses. To our
knowledge ours is the ﬁrst report of ERA and XLA.
Anti-B cell therapies, such as Rituximab have recently
been shown to be an eﬀective therapy in selective forms of
noninfectious inﬂammatory arthritis [4]. However in this
child, inﬂammatory arthritis developed in the absence of B-
cell function. The exact mechanism by which this occurred
is not known but it is likely that T-cell dysregulation, eitherInternational Journal of Rheumatology 3
duetoorindependentoftheabsenceofBcells,wasprimarily
responsible for ERA in our patient.
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